Search Medical Condition
Please enter condition
Please choose location from dropdown

Kerava, Finland Clinical Trials

A listing of Kerava, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (15) clinical trials

AZD8601 Study in CABG Patients

This is a randomized, double-blind, placebo-controlled, sequential design, multicentre study in patients with moderately impaired systolic function undergoing CABG surgery. Twenty four (24) patients scheduled for elective bypass surgery will be randomized (up to approximately 33 patients if replacements are needed). The objective is to investigate safety and tolerability of ...

Phase

0.07 miles

Learn More »

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal pentavalent vaccine.

Phase

4.4 miles

Learn More »

Efficacy of a Plant-derived Quadrivalent VLP Vaccine in the Elderly

This randomized, observer-blind, placebo-controlled multicenter, Phase 3 study will be conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins expressed as VLPs for the 2018-2019 influenza virus strains. Approximately ...

Phase

4.4 miles

Learn More »

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries. The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the ...

Phase

4.4 miles

Learn More »

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13 in Healthy Infants (V114-031/PNEU-LINK)

This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13 in healthy infants. This study will include both full-term infants (37 weeks gestational age) and premature infants (<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogenicity Substudy, which will assess ...

Phase

4.4 miles

Learn More »

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

The RSV PED-011 study is indicated as a Phase 1 in the study design due to programming limitations. In fact, the study is considered a Phase 1/2 and is designed to evaluate the safety, reactogenicity and immunogenicity of the RSV candidate vaccine when administered to infants aged 6 and 7 ...

Phase

4.4 miles

Learn More »

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Healthy infants and toddlers will receive MenACYW conjugate vaccine or Nimenrix, and routine pediatric vaccines. All participants will be assessed for immunogenicity before and after vaccination. Safety will be assessed throughout the study period, and includes solicited injection site and systemic reactions as well as unsolicited adverse events after each ...

Phase

4.4 miles

Learn More »

Safety Tolerability and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)

This study will evaluate the safety, tolerability, and efficacy of Human Cytomegalovirus (CMV) vaccine V160 administered in a 2-dose or 3-dose regimen in healthy seronegative women 16 to 35 years of age. Participants will receive blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day ...

Phase

4.4 miles

Learn More »

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020/PNEU-TRUE)

The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114. The primary hypothesis is that all 3 lots of V114 are equivalent as measured by the serotype-specific OPA GMTs for ...

Phase

4.4 miles

Learn More »

Study to Evaluate the Safety Tolerability and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants Children and Adolescents (V114-024)

This is a study of V114 in healthy children who are either pneumococcal vaccine-nave or who previously received a partial or full regimen of pneumococcal conjugate vaccine (PCV). Participants will be randomly assigned, in a 1:1 ratio, to receive either V114 or Prevnar 13. Randomization will be stratified by age ...

Phase

4.4 miles

Learn More »